The use of allo-HSCT in NF-κB essential modulator (NEMO) deficiency caused by hypomorphic IKBKG mutations remains a controversial topic. Initial observations led to widespread concerns that allo-HSCT preparative regimens were poorly tolerated; 1 and, in those who escaped chemotherapy-associated toxicity, there were additional concerns that the underlying somatic tissue defects were exacerbated. 2, 3 In particular, it was proposed that introducing a competent immune system into a NEMO-deficient host results in severe, chronic intestinal inflammation and infection as a response to increased translocation of enteric bacteria. 4 As more patients have been identified, it has become apparent that the somatic features that result from hypomorphic IKBKG mutations are quite variable. This phenotypic variability supports the notion that the effect of introducing a competent immune system into NEMOdeficient patients may also be variable. We report allo-HSCT in two patients with hypomorphic IKBKG mutations with successful outcomes, including full immune reconstitution.
Allo-HSCT was carried out in patient 1, a 2-year-old boy with Pneumocystis jirovecii pneumonia and CMV viremia, who was found to have a novel mutation in the first coiled-coil domain of IKBKG, c.337G4A (p.Asp113Asn). Clinical and laboratory features were previously reviewed and were significant for the absence of the somatic problems of oligodontia, ectodermal dysplasia or chronic gastrointestinal (GI) disease. 5 Despite both impaired natural killer (NK) cell function and impaired T-cell receptor (TCR) signaling, Toll-like receptor (TLR) signaling appeared to be intact. 5 The patient received a myeloablative conditioning regimen consisting of BU, CY and equine antithymocyte globulin (ATG) followed by 10/10-matched, unrelated umbilical cord blood allo-HSCT. Post transplant, the patient developed allergies to sulfa and walnuts but did not develop chronic GI symptoms. Complete donor chimerism was achieved and T-and B-cell reconstitution was complete. He was able to discontinue replacement IgG therapy, and he responded appropriately to both conjugate and live virus vaccines. He remains well, 6 years post allo-HSCT.
Patient 2 was a 2-year-old boy with a history of methicillinresistant Staphylococcus aureus subdural abscess in whom a first coiled-coil domain IKBKG mutation was identified, c.437T4G (p. Val146Gly). Clinical and laboratory features were reviewed previously. 6 In contrast to patient 1, patient 2 had features of ectodermal dysplasia including oligodontia and conical teeth. A sweat test was normal. Pre-transplant morbidity included CMV viremia, severe eczema, diarrhea, vomiting and failure to thrive that necessitated gastric tube feeding. Pre-transplant immune features included eosinophilia, mild T-cell lymphopenia and the combination of low IgM and IgG but elevated IgA. The patient underwent a myeloablative conditioning regimen consisting of BU, CY and rabbit ATG followed by 10/10-matched, unrelated umbilical cord blood allo-HST. Post transplant, the patient remained free of chronic morbidity. Complete donor chimerism was achieved and T-and B-cell reconstitution was complete. He was able to discontinue replacement IgG therapy, and he responded appropriately to both conjugate and live virus vaccines. Post transplant, the chronic GI symptoms resolved. He remains well, 4 years post allo-HSCT.
There have been nine published reports of patients with hypomorphic IKBKG mutations who received an allo-HSCT ( Table 1) . [1] [2] [3] [7] [8] [9] [10] Six of the patients were reported to have survived at the time of their respective publication. Here, we add an additional two patients who achieved long-term survival. To the preexisting reports, this report adds the second allo-HSCT in a NEMO-deficient patient without ectodermal dysplasia. The first report by Imamura et al. 10 documented a favorable outcome as well. It is currently unknown whether absence of ectodermal dysplasia influences transplant outcomes in patients with IKBKG mutations, but this report provides further information to consider as a favorable prognostic indicator.
Of note, the patients reported here did not suffer from posttransplant GI complications. Four of the nine previously reported patients suffered from persistent GI disease after transplant. The patient reported by Pai et al. 3 had an inflammatory colitis characterized by neutrophilic infiltration before transplant, GVHD following transplant and chronic GI infection following resolution of GVHD. The patient reported by Fish et al. 2 showed histologic evidence of GVHD on colonic biopsy following transplant. Neither patient 1 nor patient 2, a patient who had chronic vomiting and failure to thrive before transplant, developed post-transplant GI disease. Likewise, the patients described by Permaul et al., 7 Tono et al. 8 and Mancini et al., 9 all of whom had varied pre-transplant GI problems, experienced resolution after transplant. As the pretransplant GI problems were varied and included inflammatory colitis, small intestinal villous atrophy, colonic polyps, and nonspecific diarrhea and vomiting, the relationship between pretransplant and post-transplant GI disease is difficult to delineate. It is clear, however, that chronic post-transplant GI problems are not intrinsic to the disorder, and therefore preexisting GI problems should not necessarily preclude HSCT.
The reasons for such variations in allo-HSCT outcomes are unclear. As can be seen in Table 1 , evidence of impairment of any of CD40, TNF receptor, TLR, TCR signaling or NK function did not predict the failure of HSCT or the achievement of endurable immune reconstitution. In addition, the location of the individual mutations within the IKBKG gene did not predict the outcome, as the p.Leu153Arg mutation, in which persistent post-transplant colitis was demonstrated, was located in close proximity to the two mutations reported above ( Figure 1) . As a result, there is little to guide the decision to transplant in patients with novel IKBKG mutations.
In summary, an additional two patients with IKBKG mutations have been transplanted successfully. In these patients, there was no chronic GI disease following transplantation, and there were no difficulties with tolerating conditioning, with engraftment or with GVHD. We were unable to identify a specific functional defect in NF-κB signaling that would differentiate these patients from those with less favorable transplant outcomes reported previously. In vitro assays of signaling pathways that use NEMO were not predictive of allo-HSCT outcome, and the location of mutations within the first coiled-coil domain of IKBKG resulted in significantly varied phenotype both before and after allo-HSCT. Taking the available information together, it appears that post-transplant complications in NEMO deficiency are not inevitable and the absence of ectodermal dysplasia may be a positive prognostic factor. 
